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and sex but also for duration and stress o f  traveling and time of 
blood sampling. Both patients and controls were asked to stop all 
medication (especially analgesics) and were asked not to use alco­
hol for at least 48 h before testing. To avoid the possible confound­
ing effect of diurnal and seasonal variation, venous blood samples 
were collected from patients and controls between 8:30 and 11:00 
a .m . on the same day. Plasma cortisol concentrations were mea­
sured in both patients and controls.
Immunophenotyping and apoptosis. Venous blood (4 mL) was 
taken in an EDTA-containing tube for white blood cell and differential 
counts. Heparinized blood was drawn for lymphocyte immunopheno­
typing by flow cytometry with dual-color direct and indirect immuno­
fluorescence [7, 12]. Monoclonal antibodies (MAbs) were used to 
identify the following cell subsets: CD4, CD8, CD 19, CD8CD28, 
CD8CD56, CD8CD1 lb, CD8CD38, and CD8HLA-DR (Central Lab­
oratory o f  the Netherlands Red Cross Blood Transfusion Service 
and Becton Dickinson Immunocytometry Systems, San Jose, CA). 
Apoptosis experiments were done as described [13] and simultane­
ously with the other immunologic tests on 4 consecutive days in 
cultured cell samples from 9 patients with CFS and their matched 
controls. In brief, PBMC were isolated by ficoll-isopaque density 
centrifugation from heparinized blood and cultured in the absence 
and presence of CD3 MAbs. Percentages o f  apoptotic cells were 
determined by in situ nick translation as described [13]. Positive 
controls included in these experiments were samples from human 
immunodeficiency virus-positive patients.
Cytokine production. Blood samples for cytokine measure­
ments were collected into 4-mL endotoxin-free EDTA tubes (Vac- 
utainer; Becton Dickinson, Rutherford, NJ). The plasma was im­
mediately processed to avoid ex vivo cytokine production and 
release. Cytokine production was measured using a whole blood 
culture system as described elsewhere [9]. Interleukin (IL)-lo:, IL- 
1/?, IL-1 receptor antagonist (IL-1RA), and tumor necrosis factor- 
a  (TN F-a) were measured with an RIA as described [9]. IL-1 a  
was also measured with an ELISA (provided by J. J. Castracane, 
Endogen, Boston). Transforming growth factor-/? (TGF-/?) was 
measured with a bioassay as described [6] and with an immunoas­
say (Quantikine; R & D Systems, Minneapolis). Active TGF-/? 
was measured in serum; then total TGF-/? was measured after 
addition o f  acetic acid and urea, which release latent TGF-/? from 
the latency-associated peptide. The sensitivities o f  the assays were 
as follows: IL-1 a ,  5 pg/mL (RIA) and 13 pg/mL (ELISA); IL-1/?, 
20 pg/mL; IL-1RA, 50 pg/mL; TN F-a, 40 pg/mL; and TGF-/?, 
200 pg/mL (bioassay), 300 pg/mL (total TGF-/?, immunoassay), 
and 125 pg/mL (active TGF-/?, immunoassay). In each assay, refer­
ence samples with known concentration o f  cytokines were tested 
concurrently. Patients and controls were tested simultaneously to 
correct for intertest variability.
Statistical analysis. Since cytokines and cell-markers are 
known to have a non-Gaussian distribution, we used the Wilcoxon 
signed rank test to evaluate differences among cytokine production 
and T cell subsets between patients and controls. We used Spear­
m an’s p to test for correlation between cytokine production, immu­
nophenotyping analysis, and clinical symptoms such as fatigue 
and depression.
Results
Immunophenotyping. Absolute lym phocyte counts were 
similar for patients with CFS (1685 ±  626/m L) and controls
(1698 ±  464/mL). The total numbers of CD2 (total T), CD4 
(helper/inducer), CD8 (suppressor/cytotoxic), and CD 19 (total 
B) lymphocytes did not differ between CFS patients and con­
trols. The proportion of CD8 cells expressing CD1 lb (suppres­
sor T cell) was significantly decreased in patients with CFS 
compared with controls (P <  .05; figure 1). We did not find 
increased expression of activation markers CD38 and HLA- 
DR on CD8 cells, nor did we find a significantly altered expres­
sion of CD28 (P = .054). There was reduced expression of 
CD56 on CD8 cells, but this was significant only after one­
tailed testing (P <  .05). Taken together, these findings indicate 
expansion of the cytotoxic T lymphocyte population with con­
comitant decrease of the suppressor T lymphocyte population. 
Percentages of apoptotic cells after overnight culture with or 
without stimulation with CD3 MAb were not different in pa­
tient and control samples (data not shown).
Cytokine production. Circulating concentrations of IL-1 a, 
IL-1/?, TNF-c*, and IL-1RA and unstimulated cytokine produc­
tion did not differ between patients and controls (data not 
shown). As shown in figure 2, TNF-a and IL-1 /? production 
after stimulation with lipopolysaccharide (LPS) was signifi­
cantly lower in CFS patients than in their matched healthy 
controls (P <  .01 and .05, respectively). Although this differ­
ence was statistically significant, there was a large overlap 
between patients and controls. No differences were found in 
circulating total TGF-/? as measured by immunoassay (1.25 ±  
0.58 vs. 1.20 ±  0.64 ng/mL, patients vs. controls) or in TGF- 
/3 as measured by bioassay. The concentration of active TGF- 
/? on immunoassay was below the detection limit for all patients 
and controls. Plasma cortisol concentrations were similar for 
patients and controls (0.36 ±  0.22 vs. 0.30 ±  0.14 mg/mL, 
respectively).
Circulating cytokine concentrations correlated well with con­
centrations found in unstimulated whole blood cultures: IL-1 a ,
r = 0.96; IL-1/?, r =  0.69; TNF-a, r =  0.45; IL-1RA, r =  
0.74 (P <  .001 for all). This is explained by the presence of 
these cytokines in plasma and the virtual absence of  ex vivo 
cytokine production in the absence of a stimulus such as LPS. 
There was a low correlation between LPS-induced production 
of IL-1/? and IL-1 a  (/* =  0.47, P <  .001), IL-1/? and TNF-a 
(r =  0.26, P <  .05), and IL-1/? and IL-1RA (r =  0.25, P < 
.05). No correlation was found between cytokine production 
and expression of  activation markers. The average level of 
fatigue using the CIS rating scale (range, 1 -7 )  was 5.8 (1.1 
SD) for CFS patients and 1.8 (0.9 SD) for healthy controls (P < 
.001). However, in patients with CFS, we found no correlation 
between CIS-subscale fatigue and LPS-stimulated production 
of cytokines.
Discussion
The data presented here are consistent with those o f  some 
previous reports [4, 7, 14] but contrast with others [6, 8, 
15]. This may be due to patient selection, choice o f  control
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Figure 1. Expression of CD l ib,  
CD28, CD38, CD56, and HLA-DR 
on CDS cells. Boxes show 25th and 
75th percentiles with median; whisk­
ers indicate range. CFS =  chronic 
fatigue syndrome. * P < .05.
group, and differences in methods o f  assessment. We in­
cluded self-referred patients in this study to avoid selection 
bias that is encountered when only patients referred to an 
infectious disease outpatient clinic are investigated. For the 
same reasons, we did not select by symptoms or previously 
detected laboratory abnormalities. For controls, we asked 
patients to bring a healthy nonfatigued neighborhood con­
trol, matched for sex and age. By doing this, we avoided
confounding effects such as duration and stress o f  traveling 
and corrected for unknown effects (e.g., environmental pol­
lution). Furthermore, we used a whole blood culture system 
to measure cytokine production. This was done for practical 
convenience, but in addition, the method may reflect the in 
vivo situation more closely since manipulation, prestimula­
tion, and possible selection o f  PBMC are minimized, and 
the role o f  plasma factors is included.
ng/mL
Figure  2. Cytokine production 
after lipopolysaccharide stimulation 
in whole blood culture at 24 h. Boxes 
show 25th and 75th percentiles with 
median; whiskers indicate range. IL 
= interleukin; TNF =  tumor necro­
sis factor; RA = receptor antagonist. 
* P <  .05; ** P <  .01.
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Previous studies have shown good correlation between IL- 
1/?, IL-1RA, and TNF-a production in whole blood cultures 
and in isolated mononuclear cell cultures [16, 17]. In contrast 
to the results of Chao et al. [6], we found significantly decreased 
IL-1/? and TNF-a production after LPS stimulation of  periph­
eral blood cells. However, they separated the cells and did not 
add autologous plasma. Taken together, it can be hypothesized 
that plasma factors that inhibit cytokine production occur in 
CFS. Several inhibitory factors could be responsible for this. 
An increased concentration of TGF-/3, as found by Chao et al. 
[6], could explain the results, as TGF-/3 is known to inhibit 
production of  proinflammatory cytokines [6]. However, our 
finding that serum TGF-/3 concentrations were similar in pa­
tients with CFS and concomitant controls does not support this 
view. As plasma cortisol measurements were normal, it seems 
unlikely that glucocorticosteroids inhibited the production of 
proinflammatory cytokines. Inhibitory cytokines, such as IL-4 
and IL-10, or mediators, such as prostaglandins, could play a 
role. Further studies are underway to elucidate this issue. In 
contrast to others [8, 14, 15], we did not find increased concen­
trations of circulating IL-1 a.
We did find decreased expression of CD l i b  on CD8 cells, 
probably indicative of in vivo-activated CD8 T cells. This was 
also reported by Landay et al. [7] and Barker et al. [4]. We 
could not, however, detect significant differences in the expres­
sion of CD38 and HLA-DR, which have been reported to be 
elevated in patients with CFS [4, 7]. Since we did not find a 
correlation between high scores on the CIS fatigue question­
naire and CD8 cell subsets (CD1 lb, CD38, and HLA-DR), we 
doubt whether alterations in these subsets are indicative of 
having active CFS, as has been suggested [7]. We considered 
the possibility that in patients with CFS, a state o f  immune 
activation could lead to programmed cell death. In apoptosis 
experiments in 9 patients and their matched controls, there was 
no obvious difference in the percentages of cells dying due to 
programmed cell death (data not shown). Therefore, our data 
do not support the hypothesis that patients with CFS have a 
state of immune activation.
Our results show that subtle immunologic abnormalities can 
be detected in a randomly selected group of patients with CFS 
compared with a matched control group. However, since there 
is a wide range in the outcome of  the immunologic tests used in 
this study, and because we did not find a significant correlation 
between symptoms and the outcome of these tests, the meaning 
of these findings is still unclear. It is clear that immunopheno- 
typing of lymphocytes or assessment of cytokine production 
can be used neither to confirm nor to reject the diagnosis of 
CFS an individual patient, nor to assess severity of illness.
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